Mr. Brand has more than three decades of pharmaceutical industry experience. Prior to Tarsa, he served as CEO and president of Cardiokine, where he led strategic and organizational development and negotiated a significant global agreement with Biogen Idec for late stage development and marketing of lixivaptan. Previously, Mr. Brand spent over 30 years at GlaxoSmithKline and its predecessor companies. Most recently, he headed the U.S. GI/CNS, product development, metabolic and cardiovascular business units, leading the U.S. launches of Paxil®, Requip® and Avandia®, the pre-launch development of Coreg®, Kytril® and Augmentin® ES/XR, and many co-marketing and licensing deals. Earlier, Mr. Brand held international senior management positions in marketing, acquisitions, business development and regional country management. He currently serves on the board of directors at Intekrin Therapeutics. Mr. Brand holds a bachelor of commerce degree from Concordia University in Montreal.
Prior to joining Tarsa, Dr. Gilligan held positions of increasing responsibility for nearly 30 years at Unigene, where he led the development of the oral calcitonin product now licensed to Tarsa. He serves as vice president of product development at Unigene, where he was project leader for the oral and nasal calcitonin programs, as well as the oral parathyroid hormone and site-directed bone growth programs. Dr. Gilligan was responsible for leading the clinical programs and successful U.S. and European regulatory registrations for the nasal calcitonin product Fortical® Nasal Spray and the injectable calcitonin product Forcaltonin® Injection. Dr. Gilligan holds a Ph.D. in pharmacology toxicology from the University of Connecticut and a master’s degree in international business from the Stillman School of Business at Seton Hall University.
Dr. Krause has over 20 years of pharmaceutical industry experience. Prior to Tarsa, he served as chief medical officer and senior vice president and head of R&D at Zelos Therapeutics, which develops osteoporosis therapies. Earlier, Dr. Krause was executive vice president and chief medical officer of Vicuron Pharmaceuticals, which was acquired by Pfizer. Previously, Dr. Krause held positions of increasing responsibility at GlaxoSmithKline and its predecessor companies, leading a number of worldwide clinical development groups and serving as vice president of medical strategy and cross-therapeutic affairs. Earlier in his career, Dr. Krause spent a decade in the practice of internal medicine. Dr. Krause holds an M.D. from Temple University School of Medicine and a B.A. from Pennsylvania State University. He has authored over 40 scientific publications and abstracts and is a Fellow of the American College of Physicians.
Mr. Maurer has more than 30 years experience in manufacturing and supply chain activities in the pharmaceutical industry. Prior to joining Tarsa, Mr. Maurer served as senior vice president of technical operations for Adolor Corporation, where he directed all manufacturing, supply and distribution activities for Adolor’s commercial product and development programs, including the final development and launch of their Entereg® capsules. Previously, Mr. Maurer was director of commercial manufacturing at ViroPharma, where he led supply chain activities through validation, launch preparation and commercial readiness. Earlier in his career, Mr. Maurer worked for more than 20 years at Schering-Plough, holding positions of increasing responsibility including managing pharmaceutical manufacturing facilities and directing production planning. Mr. Maurer holds a B.S. in biology from Rensselaer Polytechnic Institute.
Dr. Wicks has over 25 years’ experience in regulatory strategic planning and execution. Prior to joining Tarsa, Dr. Wicks was vice president of regulatory affairs and quality assurance at Mt Cook Pharma. Previously, he served as vice president of regulatory affairs/acting vice president of medical affairs at Odyssey Pharmaceuticals. Prior to Odyssey, Dr. Wicks was senior director, global regulatory affairs at Purdue Pharma. Previously, Dr. Wicks served in positions of increasing responsibility at several sanofi-aventis predecessor companies, including vice president of regulatory affairs at Sanofi, where he played a key role in the regulatory strategy that led to approval of Plavix® and directed early clinical efforts for the bisphosphonate Skelid®. At the Rorer/Armour companies, (predecessors to Aventis) he led a team responsible for the registration of salmon calcitonin in Japan. Dr. Wicks holds a Ph.D. in physiology from Georgetown University and a B.S. in biology from the University of Maine. He completed an NIH post-doctoral fellowship at Georgetown University Medical Center.